Adding to much shorter client recruitment timelines and broadened chances for involvement in domestic and worldwide medical trials
KAWASAKI, Japan, November 19, 2026 – (JCN Newswire) – Fujitsu Japan Limited [1] (Fujitsu Japan), together with the National Cancer Center Hospital East [2] (NCCHE) and U.S.-based Paradigm Health, Inc. [3] (Paradigm ), performed joint research study into using a Large Language Model (LLM) and Paradigm’s scientific trial matching platform, “Paradigm Platform” [4]to support the recognition of possible prospects for scientific trials of brand-new drugs. The research study verified the efficiency of the technique in considerably enhancing the performance of the prospect recognition procedure.
In between June and completion of October 2026, the partners performed a confirmation research study utilizing information from 22,334 clients in the Department of Respiratory Medicine, replicating a scientific trial targeting clients with EGFR gene [5] anomalies. The procedure included utilizing an LLM to structure client information from electronic medical records and connecting this information to the “Paradigm Platform” for matching. As an outcome, it was validated that AI might determine 57 concern prospects in addition to the scientific proof for these choices.
Structure on the outcomes of this research study, Fujitsu Japan will continue with the commercialization of a service to support the whole procedure from prospect screening to medical trial registration, going for a launch by the end of 2027. Through this service, the business intends to promote involvement in scientific trials for brand-new drugs and add to broadening treatment chances for clients.
Background
The concern of “drug loss,” where brand-new treatments offered overseas are not established or authorized in Japan, is a pushing social difficulty. To resolve this, there is an immediate requirement to promote medical trials for brand-new drugs. In the last few years, customized medication based upon hereditary anomalies and biomarkers [6] has actually advanced, especially in oncology, making the requirements for scientific trial involvement progressively intricate. Medical experts should adequately examine info distributed throughout electronic medical records, treatment histories, test outcomes, and genomic information. This positions a substantial concern on medical personnel, not just impacts the preparation and development of medical trials, however likewise acts as a consider clients missing out on chances to think about brand-new treatment choices. Distinctions in medical information formats and the occurrence of disorganized information in Japanese electronic medical records produce barriers for international information usage.
Joint Research Overview
In this joint research study, which started in June 2026, Fujitsu Japan, the NCCHE, and Paradigm made use of LLMs to structure disorganized information -such as patient medical records, treatment histories, and genomic info- essential for scientific trial eligibility evaluation [7]This was then utilized to validate the application of the “Paradigm Platform,” which has a tested performance history in the United States.
Particularly, in a confirmation procedure imitating a medical trial for clients with EGFR gene anomalies, Fujitsu Japan carried out information processing, consisting of anonymization and structuring utilizing LLMs, on electronic medical record info for 3,027 lung cancer clients out of 22,334 breathing clients at the NCCHE, and connected this information to the “Paradigm Platform.” Paradigm examined and matched the information of 540 clients amongst these 3,027 with EGFR gene anomalies, based upon 5 requirements utilized to figure out medical trial eligibility, effectively determining 57 concern prospects. Subsequent evaluation by doctors of the scientific records provided by the AI as proof validated that 51 of these people were appealing prospects.
Formerly, scientific trial prospect recognition depended on physician– such as doctors and medical research study planners– to determine prospects and by hand evaluation specific medical records based upon their own experience and understanding. The outcomes of this research study verified that by using AI and the “Paradigm Platform,” medical organizations can thoroughly identify the eligibility of target clients for scientific trials based upon standardized requirements, without depending on private proficiency. By recognizing prospects through automated over night processing, the system lowered the number of client records needing manual evaluation by roughly 89%, showing the possible to ease the problem on medical personnel and speed up medical trial chances for clients.
Keep in mind: These outcomes represent the prospects determined throughout this joint research study and do not ensure their real involvement in scientific trials. Last eligibility is identified by doctors based upon trial requirements and the client’s approval.
Future Plans
Based upon the outcomes of this joint research study, Fujitsu Japan intends to advertise a service that supports the end-to-end procedure from medical trial prospect recognition to client registration, with a target launch by the end of 2027. Moving forward, the partners will promote the adoption of this option at medical organizations throughout Japan to assist broaden their capability to perform scientific trials. By supplying more clients with chances to take part in medical trials, Fujitsu Japan will add to quicker medical trial initiation and client registration, eventually assisting in wider access to brand-new treatments.
Fujitsu Japan promotes the “Uvance” [8] service design, devoted to attaining organization change and producing social worth through AI. The business will continue to utilize “Uvance” to simplify and advance medical trials, intending to get rid of drug loss and supply greater quality health care to every client.
[1] Fujitsu Japan Limited:
Head workplace: Kawasaki, Kanagawa, Japan; Representative Director, CEO: Izuru Kokubu.
[2] National Cancer Center Hospital East:
Place: Kashiwa, Chiba, Japan; Hospital Director: Toshihiko Doi. A center developed and run by the National Cancer.
[3] Paradigm Health, Inc.:
Head workplace: Columbus, Ohio, USA; CEO: Kent Thoelke.
[4] Paradigm Platform:
A medical trial matching platform offered by Paradigm to support medical trial operations, consisting of client population analysis, trial website choice, eligibility examination, and prospect recognition.
[5] EGFR gene:
A gene that produces the EGFR protein. Anomalies in this gene are substantial signs for treatment and scientific trial eligibility in conditions such as non-small cell lung cancer.
[6] Biomarker:
A biological indication utilized to objectively assess illness status or reaction to treatment.
[7] Eligibility Assessment:
The procedure of confirming a client’s medical records versus particular involvement requirements for a medical trial to figure out if the client satisfies those requirements.
[8] Uvance:
An organization design dedicated to understanding consumer change and developing social worth in a period where AI is improving the world.
About Fujitsu
Fujitsu’s function is to make the world more sustainable by developing rely on society through development. As the digital change partner of option for consumers around the world, our 100,000 workers work to fix a few of the best obstacles dealing with mankind. Our series of services and services make use of 5 essential innovations: AI, Computing, Networks, Data & & Security, and Converging Technologies, which we combine to provide sustainability improvement. Fujitsu Limited (TSE:6702) reported combined incomes of 3.5 trillion yen (US$ 23 billion) for the ended March 31, 2026 and stays the leading digital services business in Japan by market share. Discover more: global.fujitsu
Press Contacts
Fujitsu Limited
Public and Investor Relations Division
Questions
Source: Fujitsu Ltd
Sectors: Healthcare & & Pharm, Artificial Intel, Clinical Trials
Copyright © 2026 JCN Newswire. All rights scheduled. A department of Japan Corporate News Network.
Discover more from PMN S.P.O.R.T.S - A PRIME MEDIA NETWORK BRAND
Subscribe to get the latest posts sent to your email.





